Gesynta Pharma

Gesynta Pharma is a privately held Swedish company located in Stockholm.

Based on research from the Karolinska Institute and the novel approach of inflamed-tissue specific vasodilation, Gesynta is developing mPGES1 inhibitors for the treatment of microvascular diseases such as systemic sclerosis. The company has recently reported positive Phase 1 data and is targeting to start a multi-centre Phase 2 study before the end of 2020.

Year of investment
2020

Sector
Drug development

Location
Stockholm, Sweden

Website
htthttps://www.gesynta.se/

Leave a Reply

Your email address will not be published. Required fields are marked *